This document summarizes key statistical considerations for designing confirmatory clinical trials comparing a Similar Biotherapeutic Product (SBP) to a Reference Biotherapeutic Product (RBP) using equivalence or non-inferiority designs. It discusses the differences between equivalence and non-inferiority trials, important factors like determining the comparability margin, sample size calculations, assay sensitivity, and different possible outcomes from analyzing the trial results. It also describes the results of a simulation study demonstrating that equivalence trials require larger sample sizes than non-inferiority trials to conclusively show equivalence between treatments.
Meta Analysis of Medical Device Data Applications for Designing Studies and R...NAMSA
Meta Analysis of Medical Device Data Applications for Designing Studies and Reinforcing Clinical Evidence discusses what meta analysis is as well as the potential benefits.
2.0.statistical methods and determination of sample sizesalummkata1
statistical methods and determination of sample size
These guidelines focus on the validation of the bioanalytical methods generating quantitative concentration data used for pharmacokinetic and toxicokinetic parameter determinations.
Meta Analysis of Medical Device Data Applications for Designing Studies and R...NAMSA
Meta Analysis of Medical Device Data Applications for Designing Studies and Reinforcing Clinical Evidence discusses what meta analysis is as well as the potential benefits.
2.0.statistical methods and determination of sample sizesalummkata1
statistical methods and determination of sample size
These guidelines focus on the validation of the bioanalytical methods generating quantitative concentration data used for pharmacokinetic and toxicokinetic parameter determinations.
Combination of informative biomarkers in small pilot studies and estimation ...LEGATO project
Background:
Biomarker candidates are defined as measurable molecules found in biological media. According to Biomarkers Definitions Working Group, 2001, biomarkers cover a rather wide range of parameters. Recently, biomarkers are used widely in medical researches, where single biomarkers may not possess the desired cause-effect association for disease classification and outcome prediction. Therefore the efforts of the researchers currently is to combine biomarkers. By new technologies like microarrays, next generation sequencing and mass spectrometry, researchers can obtain many biomarker candidates that can exceed tens of thousands. To avoid wasting money and time, it is suggested to control the number of patients strictly. However, pilot studies usually have low statistical power which reduces the chance of detecting a true effect .
This presentation is aimed at presenting the issues associated with subgroup analyses in clinical trials: the different types of subgroup analyses and the statistical issues associated with the conduct of subgroup analyses.
Sample size and how to calculate it
- Why sample size is important
- Alpha and beta errors
- Main outcome and Effect size
- Practical examples using Means-Proportions-Correlation- Confidence Interval
Practical Methods To Overcome Sample Size ChallengesnQuery
Watch the video at: https://www.statsols.com/webinars/practical-methods-to-overcome-sample-size-challenges
In this webinar hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - we will examine some of the most common practical challenges you will experience while calculating sample size for your study. These challenges will be split into two categories:
1. Overcoming Sample Size Calculation Challenges
(Survival Analysis Example)
We will examine practical methods to overcome common sample size calculation issues by focusing in on one of the more complex areas for sample size determination; Survival analysis. We will cover difficulties and potential issues surrounding challenges such as:
Drop Out: How to deal with expected dropouts or censoring. We compare the simple loss-to-follow-up method and integrating a dropout process into the sample size model?
Planning Uncertainty: How best to deal with the inevitable uncertainty at the planning stage? We examine how best to apply a sensitivity analysis and Bayesian approaches to explore the uncertainty in your sample size calculations.
Choosing the Effect Size: Various approaches and interpretations exist for how to find the effect size value. We examine those contrasting interpretations and determine the best method and also how to deal with parameterization options.
2. Overcoming Study Design Challenges
(Vaccine Efficacy Example)
The Randomised Controlled Trial (RCT) is considered the gold standard in trial design in drug development. However, there are often practical impediments which mean that adjustments or pragmatic approaches are needed for some trials and studies.
We will examine practical methods how to overcome common study design challenges and how these affect your sample size calculations. In this webinar, we will use common issues in vaccine study design to examine difficulties surrounding issues such as:
Case-Control Analysis: We will examine how to deal with study constraints and how to deal with analyses done during an observational study.
Alternative Randomization Methods: How best to address randomization in your vaccine trial design when full randomization is difficult, expensive or impractical. We examine how sample size calculations are affected with cluster or Mendelian randomization.
Rare Events: How does an outcome being rare affect the types of study design and statistical methods chosen in your study.
In clinical trials and other scientific studies, an interim analysis is an analysis of data that is conducted before data collection has been completed. If a treatment is particularly beneficial or harmful compared to the concurrent placebo group while the study is on-going, the investigators are ethically obliged to assess that difference using the data at hand and to make a deliberate consideration of terminating the study earlier than planned.
In interim analysis, whenever a new drug shows adverse effect on human being while testing the effectiveness of several drugs, we immediately stop the trial by taking into account the fact that maximum number of patients receive most effective treatment at the earliest stage. Interim analysis is also used to possibly reduce the expected number of patients and to shorten the follow-up time needed to make a conclusion. One wouldn't have to spend extra money if he/she already have enough evidence about the outcome. In this presentation, the total sample size is divided into four equal parts to perform the analysis and decision is made based on each individual step.
When designing a clinical study, a fundamental aspect is the sample size. In this article, we describe the rationale for sample size calculations, when it should be calculated and describe the components necessary to calculate it. For simple studies, standard formulae can be
used; however, for more advanced studies, it is generally necessary to use specialized statistical software programs and consult a biostatistician. Sample size calculations for non-randomized studies are also discussed and two clinical examples are used for illustration
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Non-inferiority and Equivalence Study design considerations and sample sizenQuery
About the webinar
This webinar examines the role of non-inferiority and equivalence in study design
In this free webinar, you will learn about:
-Regulatory information on this type of study design
-Considerations for study design and your sample size
-Practical worked examples of
--Non-inferiority Testing
--Equivalence Testing
Duration - 60 minutes
Speaker: Ronan Fitzpatrick, Head of Statistics, Statsols
Watch the video at: https://www.statsols.com/webinars
Combination of informative biomarkers in small pilot studies and estimation ...LEGATO project
Background:
Biomarker candidates are defined as measurable molecules found in biological media. According to Biomarkers Definitions Working Group, 2001, biomarkers cover a rather wide range of parameters. Recently, biomarkers are used widely in medical researches, where single biomarkers may not possess the desired cause-effect association for disease classification and outcome prediction. Therefore the efforts of the researchers currently is to combine biomarkers. By new technologies like microarrays, next generation sequencing and mass spectrometry, researchers can obtain many biomarker candidates that can exceed tens of thousands. To avoid wasting money and time, it is suggested to control the number of patients strictly. However, pilot studies usually have low statistical power which reduces the chance of detecting a true effect .
This presentation is aimed at presenting the issues associated with subgroup analyses in clinical trials: the different types of subgroup analyses and the statistical issues associated with the conduct of subgroup analyses.
Sample size and how to calculate it
- Why sample size is important
- Alpha and beta errors
- Main outcome and Effect size
- Practical examples using Means-Proportions-Correlation- Confidence Interval
Practical Methods To Overcome Sample Size ChallengesnQuery
Watch the video at: https://www.statsols.com/webinars/practical-methods-to-overcome-sample-size-challenges
In this webinar hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - we will examine some of the most common practical challenges you will experience while calculating sample size for your study. These challenges will be split into two categories:
1. Overcoming Sample Size Calculation Challenges
(Survival Analysis Example)
We will examine practical methods to overcome common sample size calculation issues by focusing in on one of the more complex areas for sample size determination; Survival analysis. We will cover difficulties and potential issues surrounding challenges such as:
Drop Out: How to deal with expected dropouts or censoring. We compare the simple loss-to-follow-up method and integrating a dropout process into the sample size model?
Planning Uncertainty: How best to deal with the inevitable uncertainty at the planning stage? We examine how best to apply a sensitivity analysis and Bayesian approaches to explore the uncertainty in your sample size calculations.
Choosing the Effect Size: Various approaches and interpretations exist for how to find the effect size value. We examine those contrasting interpretations and determine the best method and also how to deal with parameterization options.
2. Overcoming Study Design Challenges
(Vaccine Efficacy Example)
The Randomised Controlled Trial (RCT) is considered the gold standard in trial design in drug development. However, there are often practical impediments which mean that adjustments or pragmatic approaches are needed for some trials and studies.
We will examine practical methods how to overcome common study design challenges and how these affect your sample size calculations. In this webinar, we will use common issues in vaccine study design to examine difficulties surrounding issues such as:
Case-Control Analysis: We will examine how to deal with study constraints and how to deal with analyses done during an observational study.
Alternative Randomization Methods: How best to address randomization in your vaccine trial design when full randomization is difficult, expensive or impractical. We examine how sample size calculations are affected with cluster or Mendelian randomization.
Rare Events: How does an outcome being rare affect the types of study design and statistical methods chosen in your study.
In clinical trials and other scientific studies, an interim analysis is an analysis of data that is conducted before data collection has been completed. If a treatment is particularly beneficial or harmful compared to the concurrent placebo group while the study is on-going, the investigators are ethically obliged to assess that difference using the data at hand and to make a deliberate consideration of terminating the study earlier than planned.
In interim analysis, whenever a new drug shows adverse effect on human being while testing the effectiveness of several drugs, we immediately stop the trial by taking into account the fact that maximum number of patients receive most effective treatment at the earliest stage. Interim analysis is also used to possibly reduce the expected number of patients and to shorten the follow-up time needed to make a conclusion. One wouldn't have to spend extra money if he/she already have enough evidence about the outcome. In this presentation, the total sample size is divided into four equal parts to perform the analysis and decision is made based on each individual step.
When designing a clinical study, a fundamental aspect is the sample size. In this article, we describe the rationale for sample size calculations, when it should be calculated and describe the components necessary to calculate it. For simple studies, standard formulae can be
used; however, for more advanced studies, it is generally necessary to use specialized statistical software programs and consult a biostatistician. Sample size calculations for non-randomized studies are also discussed and two clinical examples are used for illustration
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Non-inferiority and Equivalence Study design considerations and sample sizenQuery
About the webinar
This webinar examines the role of non-inferiority and equivalence in study design
In this free webinar, you will learn about:
-Regulatory information on this type of study design
-Considerations for study design and your sample size
-Practical worked examples of
--Non-inferiority Testing
--Equivalence Testing
Duration - 60 minutes
Speaker: Ronan Fitzpatrick, Head of Statistics, Statsols
Watch the video at: https://www.statsols.com/webinars
· Reflect on the four peer-reviewed articles you critically apprai.docxVannaJoy20
· Reflect on the four peer-reviewed articles you critically appraised in Module 4, related to your clinical topic of interest and PICOT.
· Reflect on your current healthcare organization and think about potential opportunities for evidence-based change, using your topic of interest and PICOT as the basis for your reflection.
· Consider the best method of disseminating the results of your presentation to an audience.
The Assignment: (Evidence-Based Project)
Part 4: Recommending an Evidence-Based Practice Change
Create an 8- to 9-slide
narrated PowerPoint presentation in which you do the following:
· Briefly describe your healthcare organization, including its culture and readiness for change. (You may opt to keep various elements of this anonymous, such as your company name.)
· Describe the current problem or opportunity for change. Include in this description the circumstances surrounding the need for change, the scope of the issue, the stakeholders involved, and the risks associated with change implementation in general.
· Propose an evidence-based idea for a change in practice using an EBP approach to decision making. Note that you may find further research needs to be conducted if sufficient evidence is not discovered.
· Describe your plan for knowledge transfer of this change, including knowledge creation, dissemination, and organizational adoption and implementation.
· Explain how you would disseminate the results of your project to an audience. Provide a rationale for why you selected this dissemination strategy.
· Describe the measurable outcomes you hope to achieve with the implementation of this evidence-based change.
· Be sure to provide APA citations of the supporting evidence-based peer reviewed articles you selected to support your thinking.
· Add a lessons learned section that includes the following:
· A summary of the critical appraisal of the peer-reviewed articles you previously submitted
· An explanation about what you learned from completing the Evaluation Table within the Critical Appraisal Tool Worksheet Template (1-3 slides)
Zeinab Hazime
Nurs 6052
10/16/2022
Evaluation Table
Use this document to complete the
evaluation table requirement of the Module 4 Assessment,
Evidence-Based Project, Part 3A: Critical Appraisal of Research
Full
APA formatted citation of selected article.
Article #1
Article #2
Article #3
Article #4
Abraham, J., Kitsiou, S., Meng, A., Burton, S., Vatani, H., & Kannampallil, T.
(2020). Effects of CPOE-based medication ordering on outcomes: an overview of systematic reviews.
BMJ Quality & Safety, 29(10), 1-2.
Alanazi, A. (2020). The effect of computerized physician order entry on mortality rates in pediatric and neonatal care setting: Meta-analysis.
Informatics in Medicine
Unlocked, 19, 100308. https.
Regulatory consideration for biosimilars by fdaGopal Agrawal
Need for biosimilars
First to approve guidelines for biosimilars
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (as per FDA)
Freshers in clinical research and regulatory affairs must go through this presentation. It will help you to understand the basis of clinical trial design as per European guidelines, which is the most preferred reference guideline. Initially, I also faced many problems to understand this concept. A student who is studying a clinical research diploma can also use this presentation for their basic understanding.
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
Review on Bioanalytical Method Development in Human Plasmaijtsrd
Bioanalytical methods are widely used to quantitate drugs and their metabolites in plasma matrices and this method are applied to study in the areas of human clinical and nonhuman study. Bioanalytical methods employed for the quantitative estimation of drugs and their metabolites plays an important role in estimation and interpretation of bioequivalence, pharmacokinetic, and toxicokinetic studies. The major bioanalytical role is method development, method validation, and sample analysis. Techniques such as high pressure liquid chromatography HPLC and liquid chromatography coupled with double mass spectrometry LCMS MS can be used for bioanalytical studies. Mayuri Gavhane | Dr. Ravindra Patil | Tejaswini Kande "Review on Bioanalytical Method Development in Human Plasma" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-7 , December 2022, URL: https://www.ijtsrd.com/papers/ijtsrd52578.pdf Paper URL: https://www.ijtsrd.com/chemistry/analytical-chemistry/52578/review-on-bioanalytical-method-development-in-human-plasma/mayuri-gavhane
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Statistical considerations for confirmatory clinical trials for similar biotherapeutic products
1. Biologicals 39 (2011) 266e269
Contents lists available at ScienceDirect
Biologicals
journal homepage: www.elsevier.com/locate/biologicals
Statistical considerations for confirmatory clinical trials for similar biotherapeutic
products
Catherine Njue*
Biostatistics Unit, Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Products and Food Branch, Health Canada, 251 Sir Frederick Banting Driveway,
AL 2201E, Tunney’s Pasture, Ottawa, ON K1A 0K9, Canada
a b s t r a c t
Keywords:
Statistical principles
Clinical trials
Equivalence design
Non-inferiority design
For the purpose of comparing the efficacy and safety of a Similar Biotherapeutic Product (SBP) to
a Reference Biotherapeutic Product (RBP), the “Guidelines on Evaluation of Similar Biotherapeutic
Products (SBPs)” issued by the World Health Organisation (WHO), states that equivalence or noninferiority studies may be acceptable. While in principle, equivalence trials are preferred, noninferiority trials may be considered if appropriately justified, such as for a medicinal product with
a wide safety margin. However, the statistical issues involved in the design, conduct, analysis and
interpretation of equivalence and non-inferiority trials are complex and subtle, and require that all
aspects of these trials be given careful consideration. These issues are important in order to ensure that
equivalence and non-inferiority trials provide valid data that are necessary to draw reliable conclusions
regarding the clinical similarity of an SBP to an RBP.
Crown Copyright Ó 2011 Published by Elsevier Ltd. All rights reserved.
1. Introduction
According to the guidelines developed by the WHO for the
evaluation of SBPs, clinical trials utilising equivalence or noninferiority designs will be acceptable for the comparison of efficacy and safety of the SBP to the RBP [1]. Equivalence trials are
preferred to ensure that the SBP is not clinically less or more
effective than the RBP when used at the same dosage(s), but noninferiority trials may be considered, if appropriately justified [1,2].
The choice of the clinical trial design is dependent on many factors,
and the specific design selected for a particular study must be
explicitly stated in the trial protocol. Specifying the design selected
is critical, given that equivalence and non-inferiority trials are
designed to test different objectives. In addition, it should also be
recognised that the statistical principles governing equivalence
and non-inferiority trials are complex and subtle, and must be
given careful consideration [3]. This article will address the
statistical principles underlying equivalence and non-inferiority
trials that must be considered in the design, conduct, analysis
and interpretation of trials for the purpose of demonstrating that
the SBP is similar to the RBP.
* Tel.: þ1 613 9141 6160; fax: þ1 613 941 8933.
E-mail address: catherine.njue@hc-sc.gc.ca.
2. Equivalence vs. non-inferiority, and the choice of the
comparability margin
An equivalence trial is designed to show that a test treatment
differs from the standard active treatment by an amount that is
clinically unimportant (the equivalence margin), while a noninferiority trial is designed to show that a test treatment is not
less effective than a standard active treatment by a small predefined margin (the non-inferiority margin) [4]. These are
different objectives, and it is vital that the specific design selected
for a particular study be explicitly stated in the trial protocol [5].
The factors that should be considered in selecting the clinical trial
design include: the product in question, the intended use of the
product, the target population and disease prevalence [1].
Irrespective of the trial design selected, the next critical step is
the determination of the comparability margin. For the equivalence
trial, both the upper and lower equivalence limits are needed to
establish that the SBP response differs from the RBP response by
a clinically unimportant amount. For a non-inferiority trial, only
one limit is required to establish that the SBP response is not
clinically inferior to the RBP response by a pre-specified margin [6].
Determination of this margin must be given careful consideration
as both sample size calculations and interpretation of study results
depend on it. In practical terms, the comparability margin is
defined as the largest difference between the SBP and the RBP that
can be judged as clinically acceptable, and should be smaller than
1045-1056/$36.00 Crown Copyright Ó 2011 Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.biologicals.2011.06.006
2. C. Njue / Biologicals 39 (2011) 266e269
differences observed in superiority trials of the RBP. The choice of
the margin is based upon a combination of clinical judgement and
statistical reasoning to deal with uncertainties and imperfect
information. Adequate evidence of the effect size of the RBP should
be provided to support the proposed margin. The magnitude and
variability of the effect size of the RBP derived from historical trials
should also be taken into consideration.
3. Sample size and power
It is important to note that equivalence and non-inferiority
designs test different hypotheses requiring different formulae for
power and sample size calculations [4]. For an equivalence trial, the
null hypothesis represents lack of equivalence between the test and
reference while for an non-inferiority trial, it represents inferiority
of the test to the reference. Therefore, sample size calculations
should be based on methods specifically designed for either
equivalence or non-inferiority trials. Details of the sample size
calculations should be provided in the study protocol. At
a minimum, the basis of estimates of any quantities used in the
sample size calculation should also be clearly explained, and are
usually derived from results of earlier trials with the RBP or published literature [6].
Determination of the appropriate sample size is dependent on
various factors including: the type of primary endpoint (e.g. binary,
quantitative, time-to event etc.), the pre-defined comparability
margin, the probability of a type I error (falsely rejecting the null
hypothesis) and the probability of a type II error (erroneously
failing to reject the null hypothesis) [4,6]. The expected rates of
patient dropouts and withdrawals should also be taken into
consideration. Keeping all factors the same, including the comparability margin, the type I error rate and the type II error rate, an
equivalence trial tends to need a larger sample size than a noninferiority trial. When estimating the sample size for equivalence
or non-inferiority trials, it is usually under the assumption that
there is no difference between the SBP and RBP. An equivalence trial
could be underpowered if the true difference is not zero. Similarly,
a non-inferiority trial could be underpowered if the SBP is actually
less effective than the RBP. To minimise the risk of an underpowered study, the equivalence or non-inferiority trial should only be
considered and designed once similarity of the SBP to the RBP has
been ascertained using all available comparative data that has been
generated between the SBP and the RBP [1]. In addition, keeping
the probability of a type II error low by increasing the study power
will increase the ability of the study to show equivalence or noninferiority of the SBP to the RBP.
4. Important principles: assay sensitivity and the constancy
assumption
Potential differences between the SBP and the RBP should be
investigated in a sensitive and well established clinical model [1,2].
The sensitivity of the clinical model is important, and there should
be some confidence in the trial’s ability to detect a difference
between the SBP and the RBP if a real difference exists. This is the
concept of assay sensitivity, and refers to the ability of a specific
trial to demonstrate a difference between treatments if such
a difference truly exists [7].
Assay sensitivity is crucial to any trial, but has different implications depending on the trial design. A superiority trial that lacks
assay sensitivity will fail to show superiority of the test treatment (a
failed study), and a superiority trial that demonstrates superiority
has simultaneously demonstrated assay sensitivity. However,
a non-inferiority or equivalence trial that lacks assay sensitivity
may find an ineffective treatment to be non-inferior or equivalent
267
and could lead to an erroneous conclusion of efficacy [4]. The effect
size of the RBP in the current non-inferiority or equivalence trial is
not measured directly relative to placebo, and assay sensitivity
must be deduced. In fact, the current non-inferiority or equivalence
trial must rely on the assumption of assay sensitivity based on
information external to the trial. Factors which can reduce assay
sensitivity include poor compliance with study medication,
concomitant medications, missing data, patient withdrawals, variability in measurements, poor trial quality etc. The design and
conduct of the non-inferiority or equivalence trial must attempt to
avoid or at least minimise these factors to ensure the credibility of
trial results.
Another important principle in equivalence and non-inferiority
trials is the constancy assumption, which means that the historical
active control effect size compared to placebo is unchanged in the
setting of the current trial [7]. To ensure the validity of the
constancy assumption, the equivalence or non-inferiority trial must
be designed and conducted in the same manner as the trial that
established the efficacy of the RBP. The study population,
concomitant therapy, endpoints, trial duration, assessments and
other important aspects of the trial should be similar to those in the
trial used to demonstrate the effectiveness of the RBP.
Trial conduct should not only adhere closely to that of the trial
used to demonstrate the effectiveness of the RBP, but it should also
be conducted with high quality to ensure assay sensitivity.
5. Data analysis and analysis populations
Data analysis from equivalence and non-inferiority studies is
generally based on the use of two-sided confidence intervals
(typically at the 95% level) for the metric of treatment effect.
Examples of metrics of treatment effect include absolute difference
in proportions, relative risk, odds ratio and hazard ratio. Analysis of
non-inferiority trials can also be based on a one sided confidence
interval (typically at the 97.5% level) [6]. For equivalence trials,
equivalence is demonstrated when the entire confidence interval
falls within the lower and upper equivalence limits. Non-inferiority
trials are one sided, and statistical inference is based only on the
upper or lower confidence limit, whichever is appropriate for
a given study [8]. For example, if a lower non-inferiority margin is
defined, non-inferiority is demonstrated when the lower limit of
the confidence interval is above this margin. Likewise, if an upper
non-inferiority margin is defined, non-inferiority is demonstrated
when the upper limit of the confidence interval is below this
margin.
In a superiority trial, analysis based on the Intent to Treat (ITT)
population is considered the primary analysis, and is considered
conservative in this setting. However, for equivalence and noninferiority trials, the ITT population is not considered conservative as it tends to bias the results towards equivalence or noninferiority. The per-protocol (PP) population excludes data from
patients with major protocol violations, and excluding data from
these patients can also substantially bias the results, especially if
a large proportion of subjects are excluded. Hence, a conservative
analysis cannot always be defined for equivalence or noninferiority trials, and this will present challenges during the analysis of the trial results [9]. Equivalence or non-inferiority trials
should be analysed based on both the ITT and PP approaches, and
both sets of results should support the conclusion of equivalence or
non-inferiority.
6. Trial results: possible outcomes and interpretation
Irrespective of the trial design, the totality of the actual observed
results obtained from the clinical trial will determine whether the
3. 268
C. Njue / Biologicals 39 (2011) 266e269
SBP and the RBP can be considered clinically similar. Fig. 1 shows
the possible results (confidence intervals) from a non-inferiority or
equivalence trial designed to compare a test to a reference for
which a higher value in the endpoint corresponds to better efficacy,
and the difference between treatments is defined as test minus
reference.
As illustrated in Fig. 1 where the lower limit of the equivalence
region also represents the non-inferiority margin, several outcomes
can be obtained from the analysis based on the confidence interval
approach. The following is an interpretation of each outcome:
1. Trial failed, regardless of objective (Test is worse than
Reference);
2. Trial failed, regardless of objective (Test is not better, but could
be worse than Reference);
3. Trial failed, regardless of objective (Trial is completely noninformative: Test could be worse than or better than
Reference);
4. Test equivalent and therefore, also non-inferior to Reference
(entire confidence interval within equivalence region);
5. Test not equivalent but non-inferior to Reference (lower limit of
confidence interval above non-inferiority margin);
6. Test not equivalent but statistically and clinically superior to
Reference (lower limit of confidence interval above equivalence
region).
For comparing the SBP to the RBP, outcome 4 is the most
desirable, but as illustrated by the simulation study described
below, such an outcome can only be obtained from an adequately
powered equivalence trial, and would be unlikely to be obtained
from a trial that was designed as a non-inferiority study.
Outcome 5 has different implications for a non-inferiority trial
compared to an equivalence trial, resulting in a successful noninferiority trial, but a failed equivalence trial. Outcome 6 would
result in a failed equivalence trial, but would be acceptable in
a non-inferiority trial if it does not matter whether the test treatment can yield a much better response than the reference [4].
However, in the context of comparing the SBP to the RBP for the
purpose of demonstrating that the SBP is not clinically less or more
effective than the RBP when used at the same dosage(s), outcome 6
is not desirable as it suggests superiority of the SBP relative to the
RBP. As stated in the WHO guidance document, such a finding, if
clinically relevant, would contradict the principle of similarity and
a post-hoc justification that a finding of statistical superiority is not
clinically relevant would be difficult to defend [1]. If similarity of
the SBP to the RBP has been ascertained prior to initiation of the
confirmatory trial, outcome 6 is expected to be a rare event. This
was revealed in the simulation study described below where the
proportion of simulated confidence intervals showing statistical
superiority was about 2%.
If the statistical superiority observed is considered clinically
relevant, then the SBP would not be considered similar to the RBP
and should be developed as a stand alone product [1,2]. This is
clearly an undesirable finding at the end of a confirmatory trial that
marks the end of the comparability exercise [1]. Demonstration
that superior efficacy of the SBP is not associated with adverse
events, if the SBP is prescribed at the same dosage as the RBP would
also be required in all cases [1,2]. To minimise the risk of a superiority finding, all comparative data that have been generated
between the SBP and the RBP should be carefully reviewed and
analysed to ensure that similarity between the SBP and the RBP has
been established with a high degree of confidence prior to initiating
the confirmatory trial [1].
7. A simulation study
A direct simulation of 95% confidence intervals for differences in
proportions was carried out. Each simulation was set up to generate
data from a non-inferiority study with a binary primary endpoint
under the assumption that the proportions in the test and reference
groups are equal. The goal of the simulation study was to demonstrate that equivalence trials require more subjects than noninferiority trials, and that an adequately powered equivalence
trial is needed to obtain outcome 4 (test equivalent to reference).
Two independent binomial samples of given sample sizes and
underlying proportions of success were generated, and the
approximate 95% two-sided confidence interval for the difference
in proportions (test proportion minus reference proportion) was
calculated for each simulation. A range of proportions was
considered, and both proportions were set equal. With the noninferiority margin set to 10%, the simulations were carried out
10,000 times, with the number of subjects in each treatment group
selected in order for each simulated study to have a specified
power. From all the simulations, the observed frequency of confidence intervals supporting claims of non-inferiority (test proportion at most 10% lower) and the observed frequency of confidence
intervals supporting claims of equivalence (entire confidence
interval within the equivalence region) were calculated.
The simulation results are summarised in Table 1. The results in
Table 1 illustrate that outcome 4 (Test equivalent to Reference:
entire confidence interval within equivalence region) can be difficult to obtain from a trial designed as a non-inferiority study, and
show that the proportion of simulated confidence intervals supporting claims of equivalence is about 20% lower (for 80% power)
and about 10% lower (for 90% power) compared to the proportion of
simulated confidence intervals supporting claims of non-
1
2
Table 1
Proportion of simulated confidence intervals supporting claims of non-inferiority or
equivalence of test to reference.
3
4
Power
Proportion
of success
(p1 ¼ p2)
Required
number of
subjects
(N1 ¼ N2)
Proportion of
confidence intervals
supporting noninferiority
Proportion of
confidence intervals
supporting
equivalence
80%
0.60
0.70
0.80
0.90
0.60
0.70
0.80
0.90
400
347
273
163
520
455
360
210
80.1%
79.9%
80.5%
80.5%
89.9%
89.7%
90.4%
90.0%
60.5%
59.5%
60.8%
60.9%
79.8%
79.3%
80.7%
80.0%
5
6
Reference
Superior
Equivalence
Region
Test
Superior
Fig. 1. Possible results (confidence intervals) from a non-inferiority or equivalence
trial.
90%
4. C. Njue / Biologicals 39 (2011) 266e269
inferiority. In other words, the absolute loss in power ranges from
about 10% to 20% depending on study power.
269
Conflict of interest
Author has no potential conflicts of interest.
8. Conclusion
Acknowledgements
Equivalence trials are preferred, and non-inferiority trials may
be considered if appropriately justified [1,2]. Prior to initiating an
equivalence or non-inferiority trial for the purpose of demonstrating that the SBP has similar efficacy and safety to the RBP,
a careful evaluation of all comparative data that have been generated between the SBP and the RBP should be performed to ensure
that similarity between the SBP and the RBP has been clearly
established. This is important, as the equivalence or non-inferiority
study marks the last step of the comparability exercise, and the
study should be initiated when there is unequivocal evidence that
the SBP can be considered similar to the RBP. It is also vital that the
protocol of the trial designed to demonstrate equivalence or noninferiority of the SBP to the RBP contains a clear statement that
this is the intention.
The choice of the RBP is critical. It should be a widely used
therapy whose efficacy in the relevant indication has been clearly
established and quantified in well-designed and well-documented
placebo controlled trials. The choice of the equivalence or noninferiority margin must be clearly justified. Equivalence and noninferiority trials require different formulae for power and sample
size calculations, and the appropriate set of formulae should be
used in each setting. Factors which reduce the assay sensitivity of
a trial should be avoided or minimised, and the equivalence or noninferiority trial must be designed and conducted in the same
manner as the trial that established the efficacy of the RBP to ensure
the constancy assumption. The totality of the data obtained from
the equivalence or non-inferiority trial will determine whether the
SBP can be considered clinically similar to the RBP.
The author thanks Mike Walsh, Centre for Vaccine Evaluation,
Biologics and Genetic Therapies Directorate, Health Canada and
Bob Li, Office of Science, Therapeutic Products Directorate, Health
Canada for their input and suggestions on the original draft; Keith
O’Rourke, Centre for Vaccine Evaluation, Biologics and Genetic
Therapies Directorate, Health Canada for the running the simulations; and Bill Casley, Centre for Vaccine Evaluation, Biologics and
Genetic Therapies Directorate, Health Canada for proof reading the
article.
References
[1] Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World
Health Organisation 2010.
[2] Guidance for Sponsors. Information and submission requirements for subsequent entry biologics (SEBs). Health Canada 2010.
[3] Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 1996;313:36e9.
[4] Hwang IK. Active-controlled noninferiority/equivalence trials: methods and
practice. In: Ralph Buncher C, Tsay Jia-Yeong, editors. Statistics in the pharmaceutical industry. New York: Chapman and Hall; 2005. p. 193e230.
[5] CPMP Working Party on Efficacy of Medicinal Products, Note for Guidance.
Biostatistical methodology in clinical trials in applications for marketing
authorizations for medicinal products. Statistics in Medicine 1995;14:1659e82.
[6] Statistical Principles for Clinical Trials. ICH Topic E 1998;9.
[7] Choice of Control Group and Related Issues in Clinical Trials. ICH Topic E 2000;
10.
[8] Guidelines on Clinical Evaluations of Vaccines. Regulatory expectations. WHO
Technical Report Series 2004;924:35e101.
[9] Snapinn SM. Non inferiority trials. Current Controlled Trials in Cardiovascular
Medicine 2000;1(1):19e21.